RxDoctor Payments Data

George Chen, MD

Hematology · Houston, TXNPI 1366757775

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (53.8%), food and beverage and gifts — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 59.3% of the total. Reporting peaked in 2023 at $4,396 and has fallen 65.4% since, to $1,522 in 2025.

$7,026in general payments, 2019–2025

Across 33 payments — averaging $212.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$4K
  • Sekisui Diagnostics LLC$1K
  • Astellas Pharma US Inc$395
  • AbbVie$275
  • Incyte Corporation$168
  • Jazz Pharmaceuticals Inc.$149
  • plus $684 from 9 others
$707,581in research payments, 2019–2025

Across 16 payments — averaging $44,224 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$609K
  • Genentech, Inc.$72K
  • Takeda Pharmaceuticals U.S.A., Inc.$27K

What the payments were for

  • Speaking & faculty fees$3,78254%
  • Food & beverage$1,95928%
  • Education$1001%
  • Gifts$1,18517%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,026 in reported general payments places this provider in the 70th percentile of 97 hematology providers in Texas.

See all hematology providers in Texas

Medicare billing

Part B allowed, 2024
$63,490
Medicare patients
148
Services billed
635

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →